Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia.
As chronic myeloid leukemia is rare in children, most data on imatinib mesylate therapy is derived from adult studies. We retrospectively evaluated pediatric (<14 years) patients with Ph+ chronic myeloid leukemia treated with imatinib mesylate, from January 2003 through June 2008. Of the 12 chronic myeloid leukemia patients (2% of all leukemias) 11 were in chronic phase while one had myeloid blast crisis. Six subsequently underwent stem cell transplantation. Five patients had grade 3-4 arthralgia requiring therapy alteration. None achieved complete molecular remission (MR) with imatinib mesylate alone. In contrast 3/6 patients post stem cell transplantation have undetectable BCR-ABL. Three patients relapsed to chronic phase (1 imatinib mesylate; 2 stem cell transplantation). Relapse free survival is 65.6% at four years and all are alive. Imatinib mesylate is effective therapy for children with chronic myeloid leukemia. However, cure probably requires stem cell transplantation. Acute toxicity of imatinib mesylate is tolerable, but long-term effects on growing children are unknown. Pediatric patients with chronic myeloid leukemia should undergo stem cell transplantation when appropriate related donors are available.
Belgaumi
Asim F
AF
Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital & Research Center, PO Box 3354, MBC 53 Riyadh 11211, Saudi Arabia. belgaumi@kfshrc.edu.sa
Al-Shehri
Ali
A
Ayas
Mouhab
M
Al-Mahr
Mohammed
M
Al-Seraihy
Amel
A
Al-Ahmari
Ali
A
El-Solh
Hassan
H
D001549:Benzamides; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate
N Engl J Med. 2006 Dec 7;355(23):2408-17
17151364
Pediatr Blood Cancer. 2009 Dec;53(6):992-5
19621426
Leuk Res. 2002 Feb;26(2):129-41
11755463
Blood. 2007 Jun 1;109(11):4686-92
17317858
Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S40-6
18978743
Leuk Res. 2009 Jul;33(7):871-5
19307018
Blood. 2004 Nov 1;104(9):2655-60
15231574
Blood. 2008 Feb 1;111(3):1039-43
17932248
Bone Marrow Transplant. 2003 Sep;32(5):459-69
12942091
J Clin Invest. 2000 Jan;105(1):3-7
10619854
Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7
12528778
Nature. 2005 Jun 30;435(7046):1267-70
15988530
Leukemia. 2006 Feb;20(2):187-92
16341042
Blood. 2008 Apr 15;111(8):4022-8
18256322
Blood. 2007 Oct 15;110(8):2828-37
17626839
Clin Cancer Res. 2006 Aug 15;12(16):4899-907
16914578
N Engl J Med. 2003 Mar 13;348(11):994-1004
12637609